Objective: To know the difference between chemerin and adipocyte fatty acid-binding protein(AFABP) levels in obese individuals with positive Toxoplasma gondii(T. gondii)immunoglobulin G(IgG) compared with negative T. ...Objective: To know the difference between chemerin and adipocyte fatty acid-binding protein(AFABP) levels in obese individuals with positive Toxoplasma gondii(T. gondii)immunoglobulin G(IgG) compared with negative T. gondii IgG.Methods: This study is a cross-sectional study by using consecutive sampling methods conducted from January to April 2013. The subjects were 57 obese individuals who were divided into obese group of positive and negative T. gondii IgG. The level of chemerin,AFABP and T. gondii IgG was done by ELISA. The data were analyzed by independent t test.Results: The results showed that the level of chemerin of positive T. gondii IgG group was significantly higher than the negative T. gondii IgG group [(70.0 ± 16.5) vs.(64.4 ± 16.1) pg/mL; P = 0.003], but there was not significant AFABP difference between seropositive and negative IgG groups [(83.6 ± 41.9) vs.(74.2 ± 36.7) pg/mL; P = 0.598].Conclusions: It can be concluded that the level of chemerin of seropositive T. gondii IgG was higher than that in the negative T. gondii IgG group.展开更多
目的探讨消渴康颗粒联合聚乙二醇洛塞那肽注射液治疗2型糖尿病的临床疗效。方法选取2020年2月—2022年1月在天津医科大学第二医院就诊的104例2型糖尿病患者,按照随机数字表法将所有患者分为对照组和治疗组,每组52例。对照组皮下注射聚...目的探讨消渴康颗粒联合聚乙二醇洛塞那肽注射液治疗2型糖尿病的临床疗效。方法选取2020年2月—2022年1月在天津医科大学第二医院就诊的104例2型糖尿病患者,按照随机数字表法将所有患者分为对照组和治疗组,每组52例。对照组皮下注射聚乙二醇洛塞那肽注射液,0.1 mg/次,1次/周。治疗组在对照组基础上口服消渴康颗粒,1袋/次,3次/d。两组在治疗30 d后统计疗效。观察两组的临床疗效,比较两组血糖指标、血糖波动指标以及脂肪型脂肪酸结合蛋白(A-FABP)、趋化素(chemerin)、白细胞介素-17(IL-17)水平。结果治疗后,治疗组的总有效率为96.15%,高于对照组的总有效率82.69%,组间比较差异显著(P<0.05)。治疗后,两组患者的空腹血糖(FPG)、糖化血红蛋白(HbA1c)、餐后2 h血糖(2 h BG)显著降低(P<0.05),治疗组FPG、HbA1c、2 h BG比对照组更低(P<0.05)。治疗后,两组的平均血糖波动幅度(MAGE)、日间血糖平均绝对差(MODD)、血糖水平标准差(SDBG)水平均明显降低(P<0.05),治疗组MAGE、MODD、SDBG水平明显低于对照组,组间差异有显著意义(P<0.05)。治疗后,两组的血清A-FABP、chemerin、IL-17水平均明显低于治疗前(P<0.05);治疗组患者的血清A-FABP、chemerin、IL-17水平低于对照组,差异有统计学意义(P<0.05)。结论消渴康颗粒联合聚乙二醇洛塞那肽注射液治疗2型糖尿病的疗效确切,可提高降糖疗效,降低血糖波动,调节A-FABP、chemerin、IL-17水平,值得临床推广运用。展开更多
基金Supported by Dean of Medical Faculty of Universitas Brawijaya and Direktorat Jendral of Higher Education,Ministry of National Education and Culture of Republic Indonesia with grant number of 0636/023-04.2.16/15/2012
文摘Objective: To know the difference between chemerin and adipocyte fatty acid-binding protein(AFABP) levels in obese individuals with positive Toxoplasma gondii(T. gondii)immunoglobulin G(IgG) compared with negative T. gondii IgG.Methods: This study is a cross-sectional study by using consecutive sampling methods conducted from January to April 2013. The subjects were 57 obese individuals who were divided into obese group of positive and negative T. gondii IgG. The level of chemerin,AFABP and T. gondii IgG was done by ELISA. The data were analyzed by independent t test.Results: The results showed that the level of chemerin of positive T. gondii IgG group was significantly higher than the negative T. gondii IgG group [(70.0 ± 16.5) vs.(64.4 ± 16.1) pg/mL; P = 0.003], but there was not significant AFABP difference between seropositive and negative IgG groups [(83.6 ± 41.9) vs.(74.2 ± 36.7) pg/mL; P = 0.598].Conclusions: It can be concluded that the level of chemerin of seropositive T. gondii IgG was higher than that in the negative T. gondii IgG group.
文摘目的探讨消渴康颗粒联合聚乙二醇洛塞那肽注射液治疗2型糖尿病的临床疗效。方法选取2020年2月—2022年1月在天津医科大学第二医院就诊的104例2型糖尿病患者,按照随机数字表法将所有患者分为对照组和治疗组,每组52例。对照组皮下注射聚乙二醇洛塞那肽注射液,0.1 mg/次,1次/周。治疗组在对照组基础上口服消渴康颗粒,1袋/次,3次/d。两组在治疗30 d后统计疗效。观察两组的临床疗效,比较两组血糖指标、血糖波动指标以及脂肪型脂肪酸结合蛋白(A-FABP)、趋化素(chemerin)、白细胞介素-17(IL-17)水平。结果治疗后,治疗组的总有效率为96.15%,高于对照组的总有效率82.69%,组间比较差异显著(P<0.05)。治疗后,两组患者的空腹血糖(FPG)、糖化血红蛋白(HbA1c)、餐后2 h血糖(2 h BG)显著降低(P<0.05),治疗组FPG、HbA1c、2 h BG比对照组更低(P<0.05)。治疗后,两组的平均血糖波动幅度(MAGE)、日间血糖平均绝对差(MODD)、血糖水平标准差(SDBG)水平均明显降低(P<0.05),治疗组MAGE、MODD、SDBG水平明显低于对照组,组间差异有显著意义(P<0.05)。治疗后,两组的血清A-FABP、chemerin、IL-17水平均明显低于治疗前(P<0.05);治疗组患者的血清A-FABP、chemerin、IL-17水平低于对照组,差异有统计学意义(P<0.05)。结论消渴康颗粒联合聚乙二醇洛塞那肽注射液治疗2型糖尿病的疗效确切,可提高降糖疗效,降低血糖波动,调节A-FABP、chemerin、IL-17水平,值得临床推广运用。